Aquestive Therapeutics (AQST)
(Delayed Data from NSDQ)
$4.50 USD
+0.58 (14.80%)
Updated Apr 18, 2024 04:00 PM ET
After-Market: $4.42 -0.08 (-1.78%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth B Momentum C VGM
Brokerage Reports
0 items in cart
Aquestive Therapeutics, Inc. [AQST]
Reports for Purchase
Showing records 141 - 160 ( 397 total )
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Top and Bottom-Line Beat; All Eyes on Libervant; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Q2: Sights Set on Libervant Dec 23 PDUFA, Pipeline Updates in H2:21
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
FDA Accepts Libervant Resubmission for Review; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Libervant NDA Resubmission Accepted, PDUFA Set for December 23, 2021
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L